RCS - Eco Animal Health Gp - Animal Health Innovation Summit

ECO Animal HealthAnnouncement

08/03/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230308:nRSH1918Sa&default-theme=true

RNS Number : 1918S  Eco Animal Health Group PLC  08 March 2023

ECO Animal Health Group plc

(''ECO" or "the Group")

(AIM: EAH)

 

Animal Health, Nutrition & Technology Innovation

 

ECO Animal Health Group plc ("ECO" or "the Group"), a leader in the
development, registration and marketing of pharmaceutical products for global
animal health markets, is pleased to announce that it will be participating at
the Animal Health, Nutrition and Technology Innovation summit and leading the
round table discussion on swine disease management.

 

Animal Health, Nutrition and Technology Innovation Europe is the sector's
premier innovation summit, showcasing the emerging companies and connecting
them with investors and strategic partners. The summit engages all key
participants in the value chain so it can address the full scope of how animal
health impacts pet owners, veterinarians, and farmers today.

 

Please find further information on the event at
https://kisacoresearch.com/events/animal-health-europe-2023
(https://kisacoresearch.com/events/animal-health-europe-2023)

 

 

Contacts:

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)

 IFC Advisory                                                   020 3934 6630

 Graham Herring

 Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 George Tzimas

 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Daniel Adams

 Carlo Spingardi

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

About ECO Animal Health

 

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and
commercialises products for livestock. Our business strategy is to generate
shareholder value by achieving the maximum sales potential from the existing
product portfolio whilst investing in Research and Development ("R&D") for
new products, particularly vaccines, and seeking to in-license new products

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUBRVROUUORAR